HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

CEP-11004

inhibitors of the c-Jun N-terminal kinase (JNK) signaling pathway

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Indoles: 200
      - Carbazoles: 32
        CEP-11004: 1
  - 3-Ring Heterocyclic Compounds
    - Carbazoles: 32
      - CEP-11004: 1

Experts

1.	Gon, Y: 1 article (09/2003)
2.	Hashimoto, S: 1 article (09/2003)
3.	Hayashi, S: 1 article (09/2003)
4.	Horie, T: 1 article (09/2003)
5.	Kitamura, N: 1 article (09/2003)
6.	Maruoka, S: 1 article (09/2003)
7.	Matsumoto, K: 1 article (09/2003)
8.	Mizumura, K: 1 article (09/2003)
9.	Shimizu, K: 1 article (09/2003)

Related Diseases

1.

09/01/2003 - "The results showed that (1) IV infection increases COX-2 expression, cPLA2 phosphorylation and PGE2 release, (2) ERK, p38 MAPK and JNK were phosphorylated, (3) CEP-11004 and PD 98059 predominantly attenuated COX-2 expression and cPLA2 phosphorylation, respectively, (4) SB 203580 did not remarkably affect COX-2 expression and cPLA2 phosphorylation, and (5) each inhibitor dose-dependently attenuated PGE2 release by various extents. "

Related Drugs and Biologics

1.	p38 Mitogen-Activated Protein Kinases
2.	Dinoprostone (PGE2)
3.	2- (2- amino- 3- methoxyphenyl)- 4H- 1- benzopyran- 4- one
4.	SB 203580